Heart fatty acid binding protein and Aβ-associated Alzheimer's neurodegeneration

Molecular Neurodegeneration

Volumn 8, Issue 1, 2013, Pages

  Desikan, Rahul S ^a   Thompson, Wesley K ^b   Holland, Dominic ^c   Hess, Christopher P ^d   Brewer, James B ^a,c   Zetterberg, Henrik ^e,f   Blennow, Kaj ^e   Andreassen, Ole A ^b,g   McEvoy, Linda K ^a   Hyman, Bradley T ^h   Dale, Anders M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF OSLO   (Norway)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Amyloid; Brain atrophy; Fatty acids; Lipids; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN C3; APOLIPOPROTEIN D; APOLIPOPROTEIN E; FATTY ACID BINDING PROTEIN; HEART FATTY ACID BINDING PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE ASSOCIATION; ENTORHINAL CORTEX; FATTY ACID METABOLISM; FEMALE; HUMAN; LIPID TRANSPORT; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN CEREBROSPINAL FLUID LEVEL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ATROPHY; BRAIN; FATTY ACID-BINDING PROTEINS; HUMANS; MAGNETIC RESONANCE IMAGING; NERVE DEGENERATION; TAU PROTEINS;

EID: 84884754006     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-8-39     Document Type: Article

References (39)

1. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Shepardson NE, Shankar GM, Selkoe DJ, Arch Neurol 2011 68 1239 1244 10.1001/archneurol.2011.203 21987540
2. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Shepardson NE, Shankar GM, Selkoe DJ, Arch Neurol 2011 68 1385 1392 10.1001/archneurol.2011.242 22084122
3. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schürmann B, Heun R, Kölsch H, van den Bussche H, Heuser I, Peters O, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Rüther E, Carrasquillo MM, Pankratz VS, Younkin SG, Hardy J, O'Donovan MC, Owen MJ, Williams J, PLoS One 2010 5 13950 10.1371/journal.pone.0013950 21085570
4. Genetic evidence for the involvement of lipid metabolism in Alzheimer's disease. Jones L, Harold D, Williams J, Biochim Biophys Acta 1801 2010 754 761
5. Linking lipids to Alzheimer's disease: cholesterol and beyond. Di Paolo G, Kim TW, Nat Rev Neurosci 2011 12 284 296 10.1038/nrn3012 21448224
6. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM, J Clin Invest 2008 118 671 682 18202749 (Pubitemid 351206556)
7. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM, Proc Natl Acad Sci USA 2012 109 15502 15507 10.1073/pnas.1206446109 22927427
8. Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Reitz C, Luchsinger J, Tang MX, Manly J, Mayeux R, Neurology 2005 64 1378 1383 10.1212/01.WNL.0000158274.31318.3C 15851727 (Pubitemid 40570505)
9. Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Reitz C, Tang MX, Manly J, Schupf N, Mayeux R, Luchsinger JA, Dement Geriatr Cogn Disord 2008 25 232 237 10.1159/000115847 18264008 (Pubitemid 351363887)
10. Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer's disease. Cheon MS, Kim SH, Fountoulakis M, Lubec G, J Neural Transm Suppl 2003 67 225 34 10.1007/978-3-7091-6721-2-20 15068254 (Pubitemid 38339937)
11. Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease. Freeman SH, Kandel R, Cruz L, Rozkalne A, Newell K, Frosch MP, Hedley-Whyte ET, Locascio JJ, Lipsitz LA, Hyman BT, J Neuropathol Exp Neurol 2008 67 1205 1212 10.1097/NEN. 0b013e31818fc72f 19018241
12. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA, Rusinek H, Wisniewski HM, Neuroscience 2000 95 721 725 10670438
13. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Blennow K, Hampel H, Weiner M, Zetterberg H, Nat Rev Neurol 2010 6 131 144 10.1038/nrneurol.2010.4 20157306
14. Cerebrospinal fluid biomarkers of Alzheimer's disease. Fagan AM, Holtzman DM, Biomark Med 2010 4 51 63 10.2217/bmm.09.83 20361010
15. The multiple roles of fatty acid handling proteins in brain. Moullé VS, Cansell C, Luquet S, Cruciani-Guglielmacci C, Front Physiol 2012 3 385 23060810
16. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K, J Alzheimers Dis 2010 22 1281 1288 20930282
17. Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. Rosén C, Mattsson N, Johansson PM, Andreasson U, Wallin A, Hansson O, Johansson JO, Lamont J, Svensson J, Blennow K, Zetterberg H, Front Aging Neurosci 2011 3 1 21442044
18. Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia. Olsson B, Hertze J, Ohlsson M, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Zetterberg H, Blennow K, Hansson O, J Alzheimers Dis 2012 Dec 19
19. Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia. Olsson B, Hertze J, Ohlsson M, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Zetterberg H, Blennow K, Hansson O, J Alzheimers Dis 2013 34 3 673 9 23254629
20. Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Ann Neurol 2009 65 403 13 10.1002/ana.21610 19296504
21. Mitochondria-associated ER membranes in Alzheimer disease. Schon EA, Area-Gomez E, Mol Cell Neurosci 2013 55 26 36 22922446
22. Membrane rafts in Alzheimer's disease beta-amyloid production. Vetrivel KS, Thinakaran G, Biochim Biophys Acta 1801 2010 860 7
23. Phospholipase A2 and arachidonic acid in Alzheimer's disease. Sanchez-Mejia RO, Mucke L, Biochim Biophys Acta 1801 2010 784 90
24. Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Steinacker P, Mollenhauer B, Bibl M, Cepek L, Esselmann H, Brechlin P, Lewczuk P, Poser S, Kretzschmar HA, Wiltfang J, Trenkwalder C, Otto M, Neurosci Lett 2004 370 36 9 10.1016/j.neulet.2004.07.061 15489013 (Pubitemid 39369852)
25. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, Locascio JJ, Wiltfang J, Kretzschmar HA, Poser S, Trenkwalder C, Otto M, Neurodegener Dis 2007 4 366 75 10.1159/000105157 17622779 (Pubitemid 47134683)
26. Serum heart-fatty acid binding protein levels in patients with Lewy body disease. Wada-Isoe K, Imamura K, Kitamaya M, Kowa H, Nakashima K, J Neurol Sci 2008 266 20 24 10.1016/j.jns.2007.08.018 17869272 (Pubitemid 351186512)
27. Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease. Ohrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, Holder D, Devanarayan V, Seeburger J, Smith AD, Blennow K, Wallin A, Dement Geriatr Cogn Dis Extra 2011 1 31 42 10.1159/000323417 22163231
28. CNS synaptogenesis promoted by glia-derived cholesterol. Mauch DH, Nägler K, Schumacher S, Göritz C, Müller EC, Otto A, Pfrieger FW, Science 2001 294 1354 7 10.1126/science.294.5545.1354 11701931 (Pubitemid 33063104)
29. Lipid rafts mediate the synaptic localization of alpha-synuclein. Fortin DL, Troyer MD, Nakamura K, Kubo S, Anthony MD, Edwards RH, J Neurosci 2004 24 6715 23 10.1523/JNEUROSCI.1594-04.2004 15282274 (Pubitemid 38993891)
30. Synphilin-1 enhances α-synuclein aggregation in yeast and contributes to cellular stress and cell death in a Sir2-dependent manner. Büttner S, Delay C, Franssens V, Bammens T, Ruli D, Zaunschirm S, de Oliveira RM, Outeiro TF, Madeo F, Buée L, Galas MC, Winderickx J, PLoS One 2010 5 13700 10.1371/journal.pone.0013700 21060871
31. The prion protein and lipid rafts. Taylor DR, Hooper NM, Mol Membr Biol 2006 23 89 99 10.1080/09687860500449994 16611584
32. The P's and Q's of cellular PrP-Aβ interactions. Westaway D, Jhamandas JH, Prion 2012 6 359 63 10.4161/pri.20675 22874673
33. Alzheimer's Disease Neuroimaging Initiative. Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, Aisen PS, Brewer JB, Hyman BT, Dale AM, Ann Neurol 2011 70 657 61 10.1002/ana.22509 22002658
34. For the Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E {varepsilon}4 Does Not Modulate Amyloid-β-Associated Neurodegeneration in Preclinical Alzheimer Disease. Desikan RS, McEvoy LK, Holland D, Thompson WK, Brewer JB, Aisen PS, Andreassen OA, Hyman BT, Sperling RA, Dale AM, AJNR Am J Neuroradiol 2013 34 505 10 10.3174/ajnr.A3267 22976236
35. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM, Neuron 2002 33 341 55 10.1016/S0896-6273(02) 00569-X 11832223 (Pubitemid 34162530)
36. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ, Neuroimage 2006 31 968 80 10.1016/j. neuroimage.2006.01.021 16530430 (Pubitemid 44183792)
37. Neuropathological stageing of Alzheimer-related changes. Braak H, Braak E, Acta Neuropathol 1991 82 239 59 10.1007/BF00308809 1759558
38. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW, Cereb Cortex 1991 1 103 16 10.1093/cercor/1.1.103 1822725
39. Nonlinear registration of longitudinal images and measurement of change in regions of interest. Holland D, Dale AM, Med Image Anal 2011 15 489 97 10.1016/j.media.2011.02.005 21388857